Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | AR | P10275 | 19/20 | 0.47 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25983090 | 0.85 | AR (0.46) | TSHRARPGR | |
| SCHEMBL13748556 | 0.82 | TSHR (0.56) | TSHRAR | |
| SCHEMBL16951116 | 0.80 | TSHR (0.34) | TSHRAR | |
| SCHEMBL4090283 | 0.78 | CYP2A6 (0.43) | TSHR | |
| SCHEMBL3911267 | 0.78 | AR (0.46) | ARPGR | |
| SCHEMBL1994873 | 0.78 | AR (0.41) | TSHRARPGR | |
| SCHEMBL29378798 | 0.78 | AR (0.41) | TSHRARPGR | |
| SCHEMBL13525505 | 0.77 | AR (0.47) | ARPGR | |
| SCHEMBL16954302 | 0.76 | AR (0.40) | TSHRARPGR | |
| SCHEMBL16960191 | 0.76 | AR (0.40) | TSHRARPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015089634-A9 | NON-STEROIDAL ANTIANDROGENS AND SELECTIVE ANDROGEN RECEPTOR MODULATORS WITH A PYRIDYL MOIETY | ENDORECHERCHE, INC. (CA) | 2016-01-14 | — | — | WO | disclosed |
| EP-2900645-A1 | 3-PHENYLISOXAZOLIN DERIVATIVES WITH HERBICIDAL ACTION | Bayer CropScience AG (DE) | 2015-08-05 | — | — | EP | disclosed |
| WO-2015089634-A1 | NON-STEROIDAL ANTIANDROGENS AND SELECTIVE ANDROGEN RECEPTOR MODULATORS WITH A PYRIDYL MOIETY | ENDORECHERCHE, INC. (CA) | 2015-06-25 | — | — | WO | disclosed |
| US-20100010093-A1 | ANTIPARASITIC AGENTS | PFIZER LIMITED (GB) | 2010-01-14 | — | — | US | disclosed |
| US-7608604-B2 | Antiparasitic agents | PFIZER LIMITED (GB) | 2009-10-27 | — | — | US | disclosed |
| CN-101272784-A | Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals | SANOFI AVENTIS (FR) | 2008-09-24 | — | — | CN | disclosed |
| US-20080194694-A1 | nematocides such as N-{1-cyano-2-[5-cyano-2-(trifluoromethyl)phenoxy]-1-methylethyl}-4-pentafluorothiobenzamide, tautomers or prodrugs, carriers and optionally a second therapeutic agent, used for treating parasitic infestations | PFIZER LIMITED (UK) | 2008-08-14 | — | — | US | disclosed |
| EP-1339701-B1 | HETEROARYL ALKYL PIPERAZINE DERIVATIVES AS FATTY ACID OXIDATION INHIBITORS | CV THERAPEUTICS INC (US) | 2007-02-14 | — | — | EP | disclosed |
| JP-2005132728-A | METHOD FOR PRODUCING METHYLTRIFLUOROMETHYLBENZOIC ACID DERIVATIVE | CENTRAL GLASS CO LTD | 2005-05-26 | — | — | JP | disclosed |
| US-6849632-B2 | Heteroaryl alkyl piperazine derivatives | CV THERAPEUTICS, INC. (US) | 2005-02-01 | — | — | US | disclosed |
| US-20040029889-A1 | Heteroaryl alkyl piperazine derivatives as fatty acid oxidation inhibitors | CV THERAPEUTICS, INC. | 2004-02-12 | — | — | US | disclosed |
| US-20030216409-A1 | Heteroaryl alkyl piperazine derivatives | CV THERAPEUTICS, INC. | 2003-11-20 | — | — | US | disclosed |
| EP-1339701-A1 | HETEROARYL ALKYL PIPERAZINE DERIVATIVES AS FATTY ACID OXIDATION INHIBITORS | CV THERAPEUTICS, INC. (US) | 2003-09-03 | — | — | EP | disclosed |
| US-6573264-B1 | Protecting skeletal muscles against damage, treating shock conditions, preserving donor tissue and organs used in transplants, treating cardiovascular diseases | CV THERAPEUTICS, INC. | 2003-06-03 | — | — | US | disclosed |
| WO-2002064576-A1 | HETEROARYL ALKYL PIPERAZINE DERIVATIVES AS FATTY ACID OXIDATION INHIBITORS | CV THERAPEUTICS, INC. (US) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194694-A1 | nematocides such as N-{1-cyano-2-[5-cyano-2-(trifluoromethyl)phenoxy]-1-methylethyl}-4-pentafluorothiobenzamide, tautomers or prodrugs, carriers and optionally a second therapeutic agent, used for treating parasitic infestations | HRH4, HRH3, HRH2 | TSHR 1063/4885AR 4573/4885PGR 3544/4885 |
| US-20040029889-A1 | Heteroaryl alkyl piperazine derivatives as fatty acid oxidation inhibitors | CPT1B, CPT1A, ALOX15 | TSHR 4541/4885AR 2560/4885PGR 4588/4885 |
| US-20030216409-A1 | Heteroaryl alkyl piperazine derivatives | ATP2A1, CPT1B, ATP2A3 | TSHR 4265/4885AR 2565/4885PGR 4681/4885 |
| US-20100010093-A1 | ANTIPARASITIC AGENTS | HRH3, CYTH3, HRH4 | TSHR 1340/4885AR 4729/4885PGR 3222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.